Cybin Inc. (OTCMKTS:CYBN – Get Free Report) fell 2% on Wednesday . The company traded as low as $8.65 and last traded at $8.82. 209,562 shares were traded during trading, an increase of 9% from the average session volume of 191,388 shares. The stock had previously closed at $9.00.
Cybin Trading Up 6.7 %
The firm has a market cap of $188.12 million, a price-to-earnings ratio of -49.53 and a beta of 0.39. The company has a fifty day moving average price of $10.19 and a 200-day moving average price of $5.43.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
See Also
- Five stocks we like better than Cybin
- 3 Monster Growth Stocks to Buy Now
- Constellation Energy: Stock Climbs on Billion-Dollar Contract
- What Are Dividend Achievers? An Introduction
- Vistra Stock: Powered for Continued Gains in the New Year
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- These 3 AI Stocks Are Ready to Lead in 2025
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
